Celecoxib for the Prevention of Colorectal Adenomatous Polyps - Arber, Nadir; Eagle, Craig J; Spicak, Julius; Rácz, István; Dite, Petr; Hajer, Jan; Zavoral, Miroslav; Lechuga, Maria J; Gerletti, Paola; Tang, Jie; Rosenstein, Rebecca B; Macdonald, Katie; et al. (The New England journal of medicine, 2006)
Keywords: Adenoma - drug therapy; Adenoma - prevention & control; Adenomatous Polyps - drug therapy; Adenomatous Polyps - prevention & control; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; Aspirin - administration & dosage; Biological and medical sciences; Cardiovascular Diseases - chemically induced; Cardiovascular Diseases - mortality; Celecoxib; Colorectal cancer; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - prevention & control; Cyclooxygenase 2 Inhibitors - administration & dosage; Cyclooxygenase 2 Inhibitors - adverse effects; Cyclooxygenase 2 Inhibitors - therapeutic use; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Diseases - chemically induced; General aspects; Humans; Kidney Diseases - chemically induced; Male; Medical research; Medical sciences; Middle Aged; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Pyrazoles - therapeutic use; Secondary Prevention; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Sulfonamides - therapeutic use; Tumors; Prostaglandin-endoperoxide synthase; Rectal disease; Adenomatous polyp; Enzyme; Enzyme inhibitor; Cyclooxygenase 2 inhibitor; Celecoxib; Colonic disease; Non steroidal antiinflammatory agent; Medicine; Prevention; Colorectal adenoma; Digestive diseases; Intestinal disease; Oxidoreductases; Benign neoplasm